Advertisement
Canada markets open in 41 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7324
    +0.0000 (+0.00%)
     

  • CRUDE OIL

    84.18
    +0.61 (+0.73%)
     

  • Bitcoin CAD

    87,836.44
    +907.69 (+1.04%)
     

  • CMC Crypto 200

    1,390.88
    -5.65 (-0.41%)
     

  • GOLD FUTURES

    2,362.40
    +19.90 (+0.85%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.6710
    -0.0350 (-0.74%)
     

  • NASDAQ futures

    17,756.75
    +189.25 (+1.08%)
     

  • VOLATILITY

    16.06
    +0.69 (+4.49%)
     

  • FTSE

    8,122.39
    +43.53 (+0.54%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6831
    +0.0010 (+0.15%)
     
MARKETS LIVE BLOG:

STOCK FUTURES JUMP, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Results from 'Magnificent Seven' duo show cloud revenue boosted by strong AI demand

DNA ALERT - Nationally Ranked Shareholder Rights Firm Labaton Sucharow is Investigating Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) for Potential Securities Violations

ACCESSWIRE
·2 min read

NEW YORK, NY / ACCESSWIRE / October 25, 2021 / Labaton Sucharow, a nationally ranked and award-winning shareholder rights firm, is investigating potential violations of the federal securities laws by Ginkgo Bioworks Holdings, Inc. (NYSE:DNA).

On October 6, 2021, short seller Scorpion Capital released a report alleging that Ginkgo Bioworks Holdings is a "colossal scam." The 175-page report alleges that Ginkgo Bioworks' business model is a "shell game," and that the company is highly dependent on related party transaction revenues. The report charges that the company is a "Frankenstein mash-up of the worst frauds of the last 20 years."

Ginkgo Bioworks Holdings went public via a deSPAC transaction with blank check company Soaring Eagle Acquisition Corporation in September 2021.

ADVERTISEMENT

Shares in Ginkgo Bioworks have fallen 20% after publication of the report.

If you currently own stock or options in Ginkgo Bioworks Holdings, Inc. and suffered a loss, click here to participate.

If you want to receive additional information and protect your investments free of charge, please contact David J. Schwartz using the toll-free number (800) 321-0476 or via email at david@labaton.com.

About the Firm

Labaton Sucharow LLP is one of the world's leading complex litigation firms representing clients in securities, antitrust, corporate governance and shareholder rights, and consumer cybersecurity and data privacy litigation. Labaton Sucharow has been recognized for its excellence by the courts and peers, and it is consistently ranked in leading industry publications. Offices are located in New York, NY, Wilmington, DE, and Washington, D.C. More information about Labaton Sucharow is available at labaton.com.

CONTACT:

David J. Schwartz
(800) 321-0476
david@labaton.com

SOURCE: Labaton Sucharow LLP



View source version on accesswire.com:
https://www.accesswire.com/669489/DNA-ALERT--Nationally-Ranked-Shareholder-Rights-Firm-Labaton-Sucharow-is-Investigating-Ginkgo-Bioworks-Holdings-Inc-NYSEDNA-for-Potential-Securities-Violations